Fermented foods have been proposed to beneficially affect glycemic control and the inflammatory state of the body, potentially by strengthening the gut barrier. However, scientific evidence for their health-promoting capabilities is scarce. We assessed the influence of the daily consumption of fresh and pasteurized sauerkraut on circulating "leaky gut" markers, inflammatory markers, blood pressure, and markers for glycemic control. Methods In this randomized crossover intervention trial, 87 healthy participants consumed 100 g/day of fresh and pasteurized sauerkraut for four weeks. Prior to each intervention phase, participants underwent a washout phase of four weeks' length during which no fermented foods were consumed. We used mixed regression models to compare assessed parameters before and after each intervention. Results Consumption of both fresh and pasteurized sauerkraut was associated with a small reduction in systolic blood pressure. Modest changes in selected markers of inflammation and glycemic control were observed following stratification by age, estimated daily fiber consumption, and to a lesser extent, BMI and sex. No change in gut barrier integrity was observed. Conclusions Live bacteria are not essential for the hypotensive potential of sauerkraut. Four weeks of daily consumption was not linked to an appreciable systemic health benefit in healthy individuals.

A man in his early 70s presented with septic shock and severe ARDS, likely after aerosolising Francisella tularensis Initial empirical treatment for community-acquired pneumonia with ceftriaxone failed, resulting in clinical deterioration with stage 3 acute kidney injury requiring dialysis and necrotising pneumonia. After pneumonic tularaemia was identified, antimicrobial therapy was transitioned to renally dosed levofloxacin, along with aggressive ICU support including prone positioning and tube thoracostomy. The patient ultimately made a full recovery, returning to his functional baseline one month after discharge.This case underscores the importance of eliciting environmental exposures in patients with severe, culture-negative pneumonia unresponsive to beta-lactams, as this should prompt consideration of inhalational tularaemia. It also highlights how pathogen-induced cytokine storm can drive catastrophic multiorgan failure and supports fluoroquinolones as a safe and effective first-line alternative to aminoglycosides in the setting of renal failure.

With the cardiovascular and kidney protective benefits of medications such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, renin-angiotensin -aldosterone system (RAAS) inhibitors, and mineralocorticoid receptor antagonists (MRAs), there are increased rates of initiation and use of combinations of these agents. The same mechanisms that allow for reduction of glomerular hypertension and blood pressure reduction limit the ability to maintain kidney perfusion in the setting of volume depletion and relative hypotension, and as a result increase the risk of acute kidney injury (AKI) development or severity. Sick day medication guidance that provides recommendations for holding medications in the setting of illness to mitigate the risk of AKI has not been widely adopted by practitioners. Confusion over criteria defining a sick day, lack of clarity as to how long to hold the medications and when to resume, concerns that this information drives patient hesitancy to use the medications, lack of data demonstrating benefit of holding medication, and concerns that patients will lose out on the therapeutic benefits of these agents due to constant interruption have fueled the arguments against regular use of these guidelines. In this Perspective, sick day medication guidance will be shown to be a valuable tool in counseling patients about the use of the medications, reduce the risk of and costs associated with an AKI episode, and ultimately promote more consistent use of these important medications.

Colorectal cancer (CRC) is a relatively common malignant tumor in the digestive system, and its prevention and treatment remain a challenging issue. The migration and invasion of CRC leads to significantly poor prognosis. Heat shock protein 60 (HSP60) is a mitochondrial chaperone that maintains the stability of mitochondrial proteins and plays an important functional role in the progression of most tumors. However, the functional role of HSP60 in the migration and invasion of CRC is still not understood. Therefore, this study investigated the expression of HSP60 in CRC tissues by using public databases, and the effect of HSP60 on the migration and invasion of CRC cells through functional experiments. The results showed that HSP60 was highly expressed in CRC tissues. Overexpression of HSP60 promotes the migration and invasion of CRC cells, enhances the stress and morphological changes of the cellular fibrin skeleton. However, shRNA knockdown HSP60 expression inhibited the progression of CRC cells and reduced the stress ability of fibrin. Moreover, public databases showed that there was a clear correlation between HSP60 and AKT in CRC tissues. Overexpression of HSP60 increased the expression levels of p-AKT and p-mTOR proteins, while knocking down HSP60 achieved the opposite result. Further used of BGT226 (20 nm), a dual inhibitor of the AKT/mTOR pathway, inhibited the migration and invasive movement of CRC cells induced by HSP60 overexpression. Furthermore, in vivo experiments further showed that overexpression of HSP60 promoted tumor growth. These results indicate that HSP60 is highly expressed in CRC tissues. Overexpression of HSP60 promotes the progression of CRC cells. This may be related to HSP60 overexpression activating AKT/mTOR signaling. These data suggest that HSP60 may be used as another important molecular target for the prevention and treatment of CRC.

Extracorporeal life support provides temporary cardiorespiratory support for patients with severe, potentially reversible cardiac and/or respiratory failure refractory to conventional measures. Its application has broadened across a wide spectrum of critical illness, yet the mechanistic basis of its physiological benefit remains incompletely defined.This review explores the mechanisms through which extracorporeal life support may confer benefit in respiratory and cardiac failure. These include restoration of gas exchange, optimization of circulatory dynamics, and mitigation of secondary organ injuries, creating conditions that facilitate tissue repair, enable adjunctive therapies, and in selected cases, provide a bridge to transplantation. In isolated respiratory failure, respiratory extracorporeal life support stabilizes gas exchange and modulates respiratory drive, enabling lung-protective ventilation and potentially attenuating ventilator- and patient self-inflicted lung injury. In cardiogenic shock, cardiac extracorporeal life support restores systemic perfusion and may reduce myocardial oxygen demand, while during cardiac arrest it may confer neuro-protective effects. In combined cardiorespiratory failure, advanced extracorporeal support modalities may augment both systemic and pulmonary circulation, supporting gas exchange and maintaining end-organ perfusion. Mechanistically, these interventions interrupt the cascade of hypoxemia- and/or hypercapnia- induced pulmonary vasoconstriction, right ventricular overload, and systemic hypoperfusion, facilitating multi-organ recovery. Optimizing patient selection, timing for extracorporeal life support initiation, and use of adjunctive therapies require a nuanced understanding of the interplay between these physiological pathways alongside careful considerations of key limitations including device-related complications, hematologic and inflammatory perturbations, and physiological trade-offs. This concise clinical review synthesizes the current literature on the mechanistic basis of extracorporeal life support in adults.